552 research outputs found
sj-docx-1-pch-10.1177_21501351211060351 - Supplemental material for Factors Associated With an Abnormal Blood Pressure Response During Exercise After Coarctation Repair
No full textSupplemental material, sj-docx-1-pch-10.1177_21501351211060351 for Factors Associated With an Abnormal Blood Pressure Response During Exercise After Coarctation Repair by Mia Pivirotto, Michael F. Swartz, Megan B. McGreevy, Nader Atallah-Yunes, Jill M. Cholette, Steven E. Lipshultz and George M. Alfieris in World Journal for Pediatric and Congenital Heart Surgery</p
Report on the International Colloquium on Cardio-Oncology (Rome, 12–14 March 2014)
No full textCardio-oncology is a relatively new discipline that focuses on the cardiovascular sequelae of anti-tumour drugs. As any other young adolescent discipline, cardio-oncology struggles to define its scientific boundaries and to identify best standards of care for cancer patients or survivors at risk of cardiovascular events. The International Colloquium on Cardio-Oncology was held in Rome, Italy, 12–14 March 2014, with the aim of illuminating controversial issues and unmet needs in modern cardio-oncology. This colloquium embraced contributions from different kind of disciplines (oncology and cardiology but also paediatrics, geriatrics, genetics, and translational research); in fact, cardio-oncology goes way beyond the merging of cardiology with oncology. Moreover, the colloquium programme did not review cardiovascular toxicity from one drug or the other, rather it looked at patients as we see them in their fight against cancer and eventually returning to everyday life. This represents the melting pot in which anti-cancer therapies, genetic backgrounds, and risk factors conspire in producing cardiovascular sequelae, and this calls for screening programmes and well-designed platforms of collaboration between one key professional figure and another. The International Colloquium on Cardio-Oncology was promoted by the Menarini International Foundation and co-chaired by Giorgio Minotti (Rome), Joseph R Carver (Philadelphia, Pennsylvania, United States), and Steven E Lipshultz (Detroit, Michigan, United States). The programme was split into five sessions of broad investigational and clinical relevance (what is cardiotoxicity?, cardiotoxicity in children, adolescents, and young adults, cardiotoxicity in adults, cardiotoxicity in special populations, and the future of cardio-oncology). Here, the colloquium chairs and all the session chairs briefly summarised what was said at the colloquium. Topics and controversies were reported on behalf of all members of the working group of the International Colloquium on Cardio-Oncology.Version of Recor
Letter by Lipshultz Regarding Article, “Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?”
No full textCorrigendum to "Peak oxygen consumption in Hodgkin's lymphoma survivors treated with mediastinal radiotherapy as a predictor of quality of life 5years later" [Prog. Pediatr. Cardiol. 39/2PA 93-98]
No full textByline: Michael Jacob Adams, Andrea K. Ng, Peter Mauch, Stuart R. Lipsitz, Paul Winters, Steven E. LipshultzAcademi
Realizing optimal care for children with cardiovascular disease: Funding challenges and research approaches
No full textRealizing optimal care for children with cardiovascular disease depends on organizing all the factors related to clinical care, research, education, and advocacy that have been reviewed in the 30 articles contained in these 3 issues of
Progress in Pediatric Cardiology. The management of congenital heart disease has changed greatly over the past few decades and continues to evolve rapidly. More than ever, contemporary practice requires a collaborative effort by a large healthcare team comprised not only of pediatric cardiac surgeons but also pediatric cardiac nurses, pediatric cardiologists, perfusion and respiratory technicians, pediatric cardiac intensivists, pediatric cardiac anesthesiologists, ultrasonographers, and MRI and catheterization laboratory technicians. All of these individuals need to clearly understand the morphology and pathophysiology of congenital heart disease, as well as the associated surgical procedures. The successful team will be the one that has worked together for many years with an evidence-based approach to surgery and to patient communication about the risks, benefits, and potential complications. Here, I review the funding aspects of pediatric cardiovascular care and cite research that has improved our understanding of pediatric cardiovascular medicine and that has improved patient outcomes in this branch of medicine
Exposure to Anthracyclines During Childhood Causes Cardiac Injury
No full textThe use of anthracyclines in the treatment of acute lymphoblastic leukemia is limited by associated cardiotoxic effects, which can result in cardiomyopathy and congestive heart failure, and may be irreversible. Anthracycline-induced cardiotoxicity in long-term survivors of childhood cancer is characterized by reduced left ventricular wall thickness and mass, which is indicative of decreased cardiac muscle and depressed left ventricular contractility which is indicative of unhealthy heart muscle. Risk factors for anthracycline-induced cardiotoxicity include high cumulative anthracycline doses, high anthracycline dose intensity, and radiotherapy. Radiotherapy in patients with cancer treated with anthracyclines can exacerbate anthracycline-induced cardiac tissue damage. Several studies have shown that cardiomyopathy disease progression can be delayed in adults by using angiotensin-converting enzyme inhibitors such as enalapril. Studies in long-term survivors of pediatric cancer showed that enalapril has significant benefits in preventing cardiac functional deterioration on a short-term basis, but this is not sustained. Anthracycline-associated cardiotoxic effects can be combatted by preventing cardiac injury during chemotherapy administration. There is evidence that dexrazoxane significantly reduces the cardiotoxicity associated with anthracyclines such as daunorubicin, doxorubicin, and epirubicin in adult patients with a wide range of tumor types. A study of the efficacy of dexrazoxane in reducing doxorubicin-induced cardiotoxicity in children and adolescents with high-risk acute lymphoblastic leukemia, showed that significantly fewer dexrazoxane-treated patients (21%) had elevated serum cardiac troponin (a biomarker of acute myocardial injury) levels than patients treated with chemotherapy alone (50%; P <.001). Dexrazoxane was also shown to have no effect on the event-free survival rate at 2.5 years, emphasizing that it does not detrimentally affect the efficacy of anthracycline therapy
- …
